# Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

> clinical trial · VERIFIED · 2026-06-29

Status: RECRUITING · Sponsor: National Heart, Lung, and Blood Institute (NHLBI) · Condition: Sickle Cell Disease, Hemolytic Anemia

- Company: National Heart, Lung, and Blood Institute (NHLBI)
- Sector: hematology
- Primary source: https://clinicaltrials.gov/study/NCT07566494

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.